Boonville doctor presented with Matthew 25 Award
Ascension St. Vincent says Dr. Steven Barnett has been given the Ascension Medical Group statewide Matthew 25 Award. Officials say the Matthew 25 Award is given to a clinician who represents the hospital's mission and values by demonstrating stewardship, wisdom and creativity. Through actions, the recipient displays 'a spirit of service to their community, good stewardship of their resources and compassion for vulnerable populations.'
New bank market leader announced for Webster County market
Dr. Barnett is a family medicine doctor with Ascension St. Vincent in Boonville. According to Ascension St. Vincent, Dr. Barnett's nomination reads in part that the reason he received this award is due to how he has served his 'communities' for many years and has served as Primary Care Physician for multiple generations of families. The nomination says Dr. Barnett is always providing high quality compassionate care to the patients he cares for.
'Eyewitness News. Everywhere you are.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
16-07-2025
- Medscape
Does Romosozumab Deserve Its Black Box Warning?
Osteoporosis drug romosozumab showed no increased risk for the development of cardiovascular (CV) events compared with anabolic osteoporosis drugs, contrary to its black box warning, new research found. 'These findings suggest there is no heightened risk for major adverse cardiovascular events in patients with osteoporosis treated with romosozumab compared to the anabolic agents teriparatide or abaloparatide,' the authors reported at ENDO 2025: The Endocrine Society Annual Meeting. 'Further observational data is required to concur with such findings, which may lead to a discontinuation of the black box warning,' they said. Romosozumab, a monoclonal antibody targeting sclerostin, has a unique dual action of anabolic properties (increasing bone formation while reducing resorption and improving bone mineral density while reducing vertebral fracture risk). The drug is injected monthly for 12 months, after which time its anabolic effects decline and patients must transition to other antiresorptive therapies, such as bisphosphonates or denosumab, to maintain gains in bone density. Although the FDA approved romosozumab for osteoporosis management, it has given a black box warning after clinical trials (including the ARCH study) comparing romosozumab with alendronate suggested an increased risk for serious CV events, including myocardial infarction, stroke, and CV death. The drug is therefore contraindicated in patients with hypocalcemia and those who have had a myocardial infarction or stroke within the previous year. However, data on those risks has been highly inconsistent, first author Maxim John Levy Barnett, MD, of Jefferson-Einstein Hospital, Philadelphia, told Medscape Medical News . 'Most previous studies on this issue show a nonsignificant trend toward a higher risk but do not reach statistical significance,' he said. Even the ARCH trial 'showed a trend of higher incidence of adverse outcomes, but it was not statistically significant,' he noted. New Findings To further investigate the risks, Barnett and colleagues evaluated data on patients with osteoporosis in the TriNetX database, including 14,760 patients treated with romosozumab and 45,302 treated with either teriparatide or abaloparatide anabolic agents. For the propensity score analysis, patients in the two groups were matched for age, sex, race, glycated hemoglobin, hypertension, chronic kidney disease, ischemic heart disease, cerebrovascular disease, diabetes, and other factors. After matching, the romosozumab group had 14,288 patients compared with 14,362 in the anabolic agent group. Patients had a mean age at baseline of 70.5 years, 94% were women — as the drug is approved in the US for women only — and 71% were White. With a mean follow-up of 5 years (including the 1-year treatment with romosozumab), there was a nonsignificant trend toward a reduced risk for CV incidents among those treated with romosozumab (relative risk [RR], 0.601; P = .0692). The romosozumab group also had significantly lower ischemic heart disease rates than the anabolic agent group (RR, 0.848; P = .0017). In addition, those receiving romosozumab had a lower risk of acute myocardial infarction (RR, 0.654; P < .0001). Likewise, acute heart failure, either systolic or diastolic, was also significantly lower in the romosozumab group (RR, 0.664; P = .0029). 'After propensity-score matching, there was still a significant reduction [with romosozumab], which was a surprise,' Barnett said. 'Three out of the 4 outcomes actually showed a significant decrease in risk with romosozumab.' 'To the best of my knowledge, similar trends have not been noted in other studies,' he said, adding that there have been no significant changes to romosozumab's treatment regimen or other factors that might explain differences in risk since the issuance of the black box warning. 'It is important to note that this was not the primary objective of the noninferiority study, and it was not powered for this endpoint,' Barnett said. The findings nevertheless add to evidence from others showing results that call into question the concerns behind the black box warning. 'There is no substantial evidence for cardiovascular risk and this medication; nonetheless, the black box warning is present,' Barnett said. Commenting on the study, Tiffany Kim, MD, of the University of California, San Francisco, who co-moderated the session, agreed that 'these are definitely interesting findings that add to growing data that romosozumab may not be associated with increased cardiovascular risk.' She noted that, as intended, 'any black box warning has a big effect on how clinicians consider and talk to a patient about the risks of a medication.' 'From a medico-legal perspective, I always inform my patient so they aren't surprised if they read this later, and so that I can document that they accept the benefits outweigh the risk for their individual situation.' 'This study adds to the reassuring literature that romosozumab may not be associated with increased risk of cardiovascular disease,' Kim said. 'In my clinical practice, I only consider anabolic therapy for my patients with severe osteoporosis at high fracture risk who really need treatment, so having more data about the CV risk helps with my clinical decision-making and with discussions with my patients about the risks and benefits of this drug.' In terms of caveats, Kim noted that 'the study did a good job of matching for medical comorbidities, but there may be other factors that cause a clinician to prescribe the drugs that are associated with cardiovascular disease.' 'This study is a helpful addition to the literature, but it's hard to be definitive in an observational study,' she added.
Yahoo
08-07-2025
- Yahoo
These 3 Strength Training Tools Will Change Your Habits And Body For The Long Haul
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." So, you want to officially commit to strength training. We're so here for it! But, no doubt, diving into a new fitness regimen as a beginner can be daunting and overwhelming. Many beginners are unsure where to start: what exercises to do, how much weight to lift, or how to get the gains while also avoiding injury. There's also an overload of conflicting information online and on social media, only adding to the confusion. This is where an expert-penned, science-backed book is incredibly helpful and motivating. And Women's Health has not one—but three!—game-changing playbooks to help you transform your routine, muscles, and mind with ease. Each resource was put together by one of our trusted certified trainers with deep knowledge of physiology, biomechanics, and training principles. Rather than relying on random workouts or trendy advice, try one of these effective roadmaps that will progress you to any fitness goal:$26.95 at at at amazon Programmed by fitness coach Nellie Barnett, CPT, The Woman's Guide to Strength Training: Dumbbells offers a structured, beginner-friendly 12‑week workout plan designed specifically for women, complete with clear photos and Barnett's expert tips to simplify free weight workouts. Barnett herself experienced a total transformation by following this routine. Strong & Fit After 40 delivers a clear, expert-designed 28-day strength-training program specifically tailored to women in their 40s and beyond. It combines efficient full-body workouts with information on joint health, metabolism, and recovery. Developed by certified trainer Ashley Nicole, CPT, who specializes in training women with autoimmune conditions, the book features easy-to-follow routines under 30 minutes, minimal equipment needs, and step-by-step photos to build strength and boost longevity. The Woman's Guide to Strength Training features a 12-week strength-building plan specifically for women—with a major focus on proper form—to burn fat, build muscle, and boost overall health. Trainer Betina Gozo, CPT, structured the evidence-based routine and made sure it is doable and effective for both gym and home workouts, helping you gain confidence and results for the long term. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Business Wire
24-06-2025
- Business Wire
CAN Community Health and Walgreens Partner for National HIV Testing Day
TAMPA, Fla.--(BUSINESS WIRE)--On National HIV Testing Day, CAN Community Health is partnering with Walgreens to support the national 'Greater Than HIV' campaign. This initiative provides free, confidential HIV testing at Walgreens locations nationwide on Friday, June 27, 2025. "This partnership with Walgreens reflects our core mission of empowering wellness," said Kal Gajraj, PhD, Chief Marketing Officer at CAN Community Health. As part of this national initiative, CAN Community Health mobile units will be stationed at select Walgreens locations across the country, offering on-site HIV testing, prevention education, and linkage to care. According to the Centers for Disease Control (CDC), approximately 1.1 million people across the United States are living with HIV today. Nearly 1 in 7 of those individuals are unaware of their status. This effort underscores the shared commitment of CAN Community Health and Walgreens to expand access to healthcare, reduce stigma, and empower individuals to take charge of their health. "Early detection through routine HIV testing is one of the most effective tools we have to stop the spread of HIV," said Steven Barnett, MD, AAHIVS, Chief Medical Officer at CAN Community Health. "By partnering with Walgreens, we are reaching people where they are, with compassion, dignity, and care." 'Greater Than HIV,' an initiative launched by The Kaiser Family Foundation (KFF), collaborated with 415 organizations and is testing at 575 Walgreens stores nationwide. This year's activation marks a record level of participation in the organization's 15-year history. Since 2011, the partnership between 'Greater Than HIV' and Walgreens has provided more than 93,000 free HIV/STD tests. "This partnership with Walgreens reflects our core mission of empowering wellness," said Kal Gajraj, PhD, Chief Marketing Officer at CAN Community Health. "By bringing free HIV testing directly into neighborhoods, we're removing barriers and providing the tools people need to stay informed, stay healthy, and live well." CAN Community Health mobile units will be located at select Walgreens locations in Arlington, Texas; Columbia, South Carolina; Las Vegas, Nevada; Norfolk, Virginia; Phoenix, Arizona, and across Florida in Cape Coral, Daytona Beach, Ft. Lauderdale, Hialeah, Jacksonville, Miami Beach, North Port, Orlando, Sarasota, and Tampa. About CAN Community Health CAN Community Health is the nation's premier resource in ending epidemics with a mission of empowering wellness. Headquartered in Tampa, Florida, CAN Community Health operates clinics nationwide across Arizona, Florida, Nevada, South Carolina, Texas, and Virginia. Since 1991, CAN Community Health has delivered high-quality care to those affected by HIV, Hepatitis C, and other sexually transmitted diseases through outreach, integrated clinical practice, advocacy, education, and research. For more information about CAN Community Health and its services, please visit
